BACKGROUND: Mucous membrane pemphigoid (MMP) is an autoimmune blistering
disease. In patients who do not respond to conventional therapy, rituximab (RTX) may be an …

Background The use of rituximab for refractory autoimmune blistering diseases is
increasing. Data related to rituximab for the treatment of mucous membrane pemphigoid …

Objective Mucous membrane pemphigoid (MMP) is an autoimmune blistering disorder with
tendency to scarring. Long term immunosuppressive treatment may be required to minimize …

Background Mucous membrane pemphigoid (MMP) still represents a potentially life-and
sight-threatening disease. In a subset of patients with severe MMP, conventional …

Mucous membrane pemphigoid (MMP) is a heterogeneous group of rare, chronic,
subepithelial autoimmune blistering diseases (AIBDs) with predominant involvement of …

Five patients were female and the mean age at the start of rituximab treatment was 57.6
years (range 39-80). The mean duration of disease before rituximab therapy was 53.4 …

DISCUSSION Our case report illustrates the successful use of adjuvant rituximab in a patient
suffering from high-risk MMP, which, in contrast to low-risk MMP, is defined as involving …

Background Mucous membrane pemphigoid (MMP) is an autoimmune disease that can lead
to fibrosis of mucous membranes and functional impairment. Biologic agents should be …

The article presents a study focusing on intravenous immunoglobulins for rituximab-resistant
mucous membrane pemphigoid (MMP). Topics include rituximab (anti-CD20) and high-dose …

Objective To determine the efficacy and safety of interventions for mucous membrane
pemphigoid (MMP). Study Design We conducted a systematic review from 2003 to 2013 …